Tina Keener
Family · Uniontown, PANPI 1164990958
Payments from drug & device makers
Across 195 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$665
- Novo Nordisk$571
- AstraZeneca$519
- Shield Therapeutics Inc$230
- Pfizer$201
- Abbott$194
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,531100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $665 |
| Novo Nordisk | 34 | $571 |
| AstraZeneca | 23 | $519 |
| Shield Therapeutics Inc | 8 | $230 |
| Pfizer | 12 | $201 |
| Abbott | 11 | $194 |
| GSK | 11 | $172 |
| Exact Sciences | 6 | $138 |
| Lilly USA, LLC | 5 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $75 |
| Astellas Pharma US Inc | 3 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Organogenesis Inc. | 2 | $55 |
| Smith+Nephew | 2 | $52 |
| UCB, Inc. | 2 | $51 |
| Dexcom, Inc. | 3 | $47 |
| Abiomed | 1 | $38 |
| Bayer | 2 | $33 |
| Boehringer Ingelheim | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Organon | 1 | $22 |
| Phadia US Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,531 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 131 | $111,661 |
| OzempicSemaglutide | 77 | $75,006 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $56,404 |
| EliquisApixaban | 60 | $49,403 |
| MounjaroTirzepatide | 23 | $26,006 |
| TrulicityDulaglutide | 25 | $25,217 |
| XareltoRivaroxaban | 26 | $17,546 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $15,604 |
| FarxigaDapagliflozin Propanediol | 25 | $14,775 |
| TrintellixVortioxetine Hydrobromide | 17 | $9,080 |
| TradjentaLinagliptin | 16 | $8,313 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $7,697 |
| CreonLipase/Protease/Amylase | 13 | $6,434 |
| BrilintaTicagrelor | 13 | $5,931 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 194 | $5,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $30 | $127,670164 claims |
| Novo NordiskOzempic | $571 | $75,00677 claims |
| GSKTrelegy Ellipta | $172 | $56,40487 claims |
| Lilly USA, LLCMounjaro, Trulicity | $84 | $51,22348 claims |
| PfizerEliquis | $201 | $49,40360 claims |
| AstraZenecaFarxiga, Brilinta | $519 | $20,70738 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $9,08017 claims |
| AbbVieCreon | $665 | $6,43413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Uniontown
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.